Tesamorelin vs AOD-9604
Side-by-side comparison of Tesamorelin, AOD-9604 — mechanism, dosing, half-life, side effects, and research status.
| Attribute | Tesamorelin Tesamorelin (GHRH Analogue) Growth Hormone | AOD-9604 hGH Fragment 176-191 (Anti-Obesity Drug 9604) Weight Loss |
|---|---|---|
| Basics | ||
| Molecular type | GHRH Analogue | hGH C-terminal Fragment |
| Amino acids | 44 | 16 |
| Molecular weight | 5,135.8 Da | 1,815.1 Da |
| Half-life | ~30 min | ~30 min |
| Route(s) | Subcutaneous | Subcutaneous, Oral (research) |
| Mechanism & Research | ||
| Primary mechanism | Tesamorelin binds and activates pituitary GHRH receptors with the full-length 44-amino-acid native GHRH sequence, producing more complete pituitary signalling than the 29-amino-acid fragments (sermorelin, CJC-1295). Its … | AOD-9604 mimics the lipolytic (fat-breaking) action of the C-terminal fragment of growth hormone at the beta-3 adrenergic receptor in adipocytes. By activating beta-3 receptors, it promotes lipolysis (fat cell triglyceri… |
| Research status | FDA Approved | Research Compound |
| Evidence summary | Tesamorelin has the most extensive human clinical trial dataset of any GHRH analogue, accumulated during its FDA approval programme. Effects on visceral adiposity, metabolic parameters, and cognitive function have been s… | AOD-9604 completed Phase 2b trials for obesity (METRO study) before development was discontinued. Despite clear mechanistic rationale and positive preclinical data, the Phase 2b trial did not demonstrate statistically si… |
| Protocol & Dosing | ||
| Typical dose | 2 mg/day | 300–500 mcg/day |
| Frequency | Once daily | Once daily |
| Duration | 26–52 weeks (clinical) | 8–12 weeks |
| Timing | Before breakfast or bedtime | Pre-workout or morning on empty stomach (for metabolic effects) |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Prohibited (WADA S2) | Prohibited (WADA S2) |
| Deeper reading | ||
| Related peptides | CJC-1295, Sermorelin, AOD-9604 | Semaglutide, Ipamorelin, Tesamorelin |
| Full profile | Read full Tesamorelin profile → | Read full AOD-9604 profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.